CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...
Seeking Alpha

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial ...
Morningstar

ToolGen Completes U.S. Patent Registration for Core CRISPR Cas9 RNP Technology; Files U.S. Lawsuit Related to CASGEVY®

SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ -- ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent and Trademark Office has ...
Science Daily

CRISPR unlocks a new way to defeat resistant lung cancer

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...
Hosted on MSN

New CRISPR leap could transform treatment for genetic diseases

Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of CRISPR advances is not only correcting single mutations in the lab but ...
techtimes

CRISPR Technology Explained: The Science of Gene Editing, DNA Modification, and Genetic Engineering Ethics Uncovered

Discover how scientists are harnessing the power of CRISPR to precisely edit DNA, revolutionizing medicine and ethics as they rewrite the very code of life. Pixabay, PublicDomainPictures CRISPR ...
The Atlantic

The Rarest of All Diseases Are Becoming Treatable

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...